We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $618B
1-Year Est. Return 30.34%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
+6.7%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+433.28%
AUM
$164B
AUM Growth
+$34B
Cap. Flow
+$21.1B
Cap. Flow %
12.82%
Top 10 Hldgs %
19.02%
Holding
8,908
New
1,440
Increased
3,569
Reduced
2,696
Closed
989

Sector Composition

Rank Sector Weight
1 Technology 6.08%
2 Financials 6.03%
3 Industrials 5.01%
4 Consumer Discretionary 4.73%
5 Healthcare 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AVID
8401
CALL
DELISTED
Avid Technology Inc
AVID
-11,400
Closed -$52K
CYTO
8402
DELISTED
Altamira Therapeutics Ltd
CYTO
0
-$15K
HEWU
8403
DELISTED
iShares Currency Hedged MSCI United Kingdom ETF
HEWU
-46,279
Closed -$1.09M
FRGI
8404
PUT
DELISTED
Fiesta Restaurant Group, Inc.
FRGI
-11,900
Closed -$226K
HCCI
8405
DELISTED
Heritage-Crystal Clean, Inc.
HCCI
-34,716
Closed -$755K
ZYNE
8406
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
-39,600
Closed -$331K
RETA
8407
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
-8,232
Closed -$256K
PRTK
8408
CALL
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
-12,600
Closed -$316K
GLCN
8409
DELISTED
VanEck China Growth Leaders ETF
GLCN
-30,745
Closed -$1.4M
FRBK
8410
DELISTED
Republic First Bancorp Inc
FRBK
-12,165
Closed -$113K
MTEM
8411
DELISTED
Molecular Templates, Inc.
MTEM
-776
Closed -$81K
WTT
8412
DELISTED
Wireless Telecom Group, Inc.
WTT
-21,285
Closed -$36K
SPPI
8413
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
-82,514
Closed -$1.49M
GLOP
8414
DELISTED
GASLOG PARTNERS LP
GLOP
-19,508
Closed -$452K
IMBI
8415
CALL
DELISTED
iMedia Brands, Inc. Class A Common Stock
IMBI
-1,900
Closed -$20K
NYMX
8416
DELISTED
Nymox Pharmaceutical Corp
NYMX
-10,646
Closed -$38.8K
DCP
8417
DELISTED
DCP Midstream, LP
DCP
-30,343
Closed -$1.06M
KSPN
8418
DELISTED
Kaspien Holdings Inc. Common Stock
KSPN
-680
Closed -$27K
ACOR
8419
DELISTED
Acorda Therapeutics
ACOR
-109
Closed -$310K
MGI
8420
PUT
DELISTED
MoneyGram International, Inc. New
MGI
-11,700
Closed -$188K
BIOC
8421
DELISTED
Biocept, Inc.
BIOC
-2
Closed -$18K
HOLD
8422
DELISTED
AdvisorShares North Square McKee Core Reserves ETF
HOLD
-12,279
Closed -$1.22M
COUP
8423
DELISTED
Coupa Software Incorporated
COUP
-105,300
Closed -$3.28M
FNI
8424
DELISTED
First Trust Chindia ETF
FNI
-14,239
Closed -$545K
RSX
8425
DELISTED
VanEck Russia ETF
RSX
-149,127
Closed -$3.27M

Similar funds

Citadel Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Citadel Advisors held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Citadel Advisors deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.

By sector, the portfolio is most concentrated in Technology at 6.1% of assets, down from 7% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.

  • Citadel Advisors's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
  • Citadel Advisors added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
  • Citadel Advisors's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
  • Citadel Advisors fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
  • Citadel Advisors's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
  • Citadel Advisors opened 1,440 new positions and closed 989 in Q4 2017.
  • Citadel Advisors's portfolio value rose 26% quarter-over-quarter to $164B.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.